Fusogenic membrane glycoproteins (FMGs) are viral envelope proteins, which bind surface receptors and induce fusion of the cell membrane. An FMG-transfected cell will fuse with neighbor cells, thus forming syncytia that die within 5 days. In this report, plasmids encoding for FMGs from Human Endogenous Retrovirus-W (HERV-W) was compared with Gibbon Ape Leukemia Virus (GALV) and feline endogenous virus RD-114 (RD). These plasmids were transfected in human non-small-cell lung cancer (NSCLC) cells in vitro or directly injected into tumors in mice. All FMGs induced the formation of syncytia containing around 50 cells. HERV-W or GALV FMGs decreased up to 80% of cell viability in vitro and inhibited tumor growth in vivo (60-70% reduction). In contrast, RD FMG was not efficient. Apoptosis played a role in the death of the syncytia, but addition of the caspase inhibitor Z-VAD-fmk had no effect, suggesting that apoptosis is not the only mechanism responsible for FMG-induced cell death. Altogether, our results demonstrate that even at very low transfection efficiency, the antitumor activity of HERV-W FMG is as effective as that of GALV in vitro and in vivo for the treatment of human lung tumors.
Introduction
Fusogenic membrane glycoproteins (FMGs) are constituent of the viral envelope. They recognize specific cell membrane receptors and play a role in viral entry into target cells by inducing fusion of the virus envelope with the membrane of its target cell. Interestingly, after being transiently transfected, an FMG-positive cell can also fuse with its neighbors, leading to the formation of multinucleated syncytia. As these syncytia are not viable and will eventually die within a few days, [1] [2] [3] FMG transfection has rapidly been identified as a potential antitumor treatment. The recruitment of FMG-negative neighboring cells is responsible for a powerful bystander effect superior to that of suicide genes such as herpes simplex virus thymidine kinase-1 (HSV-TK). 3, 4 This has been demonstrated after viral delivery of the Gibbon Ape Leukemia Virus FMG (GALV) or of the measles virus proteins F and H (MV-F and MV-H) in human tumor xenografts in vivo. [4] [5] [6] [7] In addition to this syncytia-mediated toxicity, FMG has also been shown to enhance the antitumor therapeutic activity of replicating adenovirus, oncolytic HSV and vesicular stomatitis virus. [8] [9] [10] [11] [12] FMG-induced cytotoxicity is not immediate. Multinucleated syncytia develop within 24 h after transfection and gradually die in 5 days. 1 The exact mechanism by which syncytia die remains unclear, but necrosis seems to play a major role since signs of mitochondrial failure, ATP depletion and autophagic degeneration were observed. 13 Although nuclear fusion was observed during the death of syncytia, the nuclei present in syncytia cannot be stained using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. 3 Procaspase-3 activation and poly (ADP-ribose) polymerase (PARP) cleavage played a minimal role in FMG-mediated cell death. 13 Addition of the caspase inhibitor Z-VAD-fmk did not inhibit syncytium death; instead, adding fructose to the culture medium partially prevented syncytia from ATP depletion and death. 1 Nevertheless, it has also been described that syncytia death showed the hallmark of apoptosis in cultured glioma cell lines, in which 80-90% syncytia induced by MV-F and MV-H or GALV FMGs were TUNEL-positive 6 days after transfection. 7 These combined results suggest that the underlying mechanism of FMG-mediated toxicity could be variable and cell linedependent.
In addition to this toxicity, the interest of FMG-based gene therapy arose also from their ability to stimulate antitumor immunity, because a dying syncytium releases exosome-like vesicles, named syncytiosomes; these vesicles can load dendritic cells with tumor-associated antigens and then mediate T-cell priming. 13 In vivo study based on vesicular stomatitis virus-FMG and murine melanoma cells demonstrated that allogeneic fusing cells can induce a specific immune priming against tumorassociated antigens and protect mice against a second challenge with the same tumor. 14, 15 In our study, FMGs from different origins were used: Human Endogenous Retrovirus-W (HERV-W), RD (Feline endogenous virus RD-114) and GALV. The HERV-W is a D-type-related retrovirus; its envelope glycoprotein, EnvERVWE1, also called syncytin, fuses human cells that express the type-D mammalian retrovirus receptor. Due to this fusogenic activity, this retrovirus is known to play a role in human placental morphogenesis. [16] [17] [18] RD and GALV are C-type mammalian retroviruses. RD envelope protein shares the common cell-surface receptor as HERV-W, 19, 20 while GALV enter cells after binding with type-III sodium-dependent phosphate transporters PiT-1. [21] [22] [23] It has been demonstrated that in D-and C-type mammalian retroviruses, the 16 C-terminal residues of the intracytoplasmic tail of these viruses' envelope proteins, called the 'R-peptide', inhibit their fusion activities. 24, 25 Thus R-less versions of these envelope proteins were used in this study, except for the HERV-W, which does not rely on the cleavage of the R-like peptide for its fusing activity. 16 In this report, FMGs from HERV-W, RD and GALV, were tested in human lung cancer cell lines in vitro, as well as in subcutaneous human lung tumors in nude mice in vivo for their anticancer activity. The mechanisms associated with FMG-mediated lung cancer cell death have been also investigated.
Materials and methods

Plasmid and construction
The FMG-coding vectors phCMV-GALVfus, phCMV-RD-Rless and phCMV-HERV-W were kindly provided by Dr Francois Loic Cosset (ENS Lyon). phCMV-GALVfus 2 and phCMV-RD-Rless 43 express the 'R-less' version of the viral envelope proteins, while phCMV-HERV-W 44 expresses the full-length HERV-W envelope protein. pCMVb (Ozyme, Saint Quentin Yvelines, France) is the mammalian reporter vector, which expresses the b-galactosidase under the transcription control of a cytomegaloviral (CMV) promoter. pcDNA3.1 (Invitrogen, Cergy Pontoise, France) served as negative control in in vitro transfections. Plasmids pcDNA-Bcl-XL and pcDNA-Bcl-2, expressing full-length Bcl-XL and Bcl-2 under control of a CMV promoter, were kindly provided by Dr Alain Puisieux (INSERM U590, France) and Professor Barbara Demeneix (UMR CNRS 5166, France), respectively.
Cell culture and transfection A549 (ATCC CCL-185) and H322 (ATCC CRL5806) are both human NSCLC cell lines. A549-luc is a subclone of A549 cell line stably transfected by the firefly luciferase expression vector pGL3-Promoter (Promega, Charbonnie`res, France). All cells were cultured at 37 1C in a humidified, CO 2 -controlled (5%) incubator, in RPMI 1640 (Invitrogen) supplied with 10% (v/v) fetal bovine serum (Invitrogen) and 0.5% (v/v) PEN-STREP (Cambrex, Verviers, Belgium). For A549-luc cells, 400 mg ml À1 of G418 (Life Technologies, Cergy, France) was supplied in the medium for selective condition of pGL3.
Shortly before transfection, A549 or H322 cells were trypsinized and resuspended in growth medium at 10 5 or 2 Â 10 5 cells ml
À1
, respectively. A 100-ml volume of 150 mM NaCl containing 1 mg of each plasmid compacted by 2 ml of jetPEI (PolyPlus Transfection, Illkirch, France; preparation according to the manufacturer's recommendation) was mixed gently with 1 ml of the medium containing cells and seeded on a coverslip in a 24-well plate.
For the co-culture experiment (Figure 3 ), the same protocol as described above was used, but after mixing PEI/DNA and the medium containing the cells, 100 ml of the mixture was seeded in each well of a 96-well plate. Six hours later, the cells were washed once by phosphatebuffered saline (PBS) and then co-cultured with 6 Â 10 3 A549-luc cells in 200 ml of growth medium.
For co-transfection (Figure 4f ), 100 ml of 150 mM NaCl containing 0.75 mg of GALV-FMG expression vector plus 0.75 mg of the Bcl-XL or Bcl-2 expression vector compacted by 3 ml of jetPEI was mixed gently with 1 ml of the medium containing 10 5 A549 cells, and seeded into a 96-well plate (200ml per well).
Z-VAD-fmk was purchased from Alexis (Lausanne, Switzerland). Z-VAD-fmk at 20-mM was supplied in the medium of the cells transfected by FMGs (Figure 4e ) 6 h after transfection. Fresh medium supplemented with Z-VAD-fmk was added every day.
Cell fixation and staining
For the transfection efficiency assay, A549 or H322 cells transfected by pCMVb were fixed 2 days after transfection in PBS containing 0.5% glutaraldehyde and 1% formaldehyde for 5 min at room temperature (RT), and then stained by incubating for 2 h at 37 1C in a solution consisting of 4 mM K 3 Fe(CN) 6 , 4 mM K 4 Fe(CN) 6 3H 2 O, 0.02% NP40, 2 mM MgCl 2 and 0.4 mg ml À1 X-Gal in PBS. Percentages of blue cells were counted under a light transmission microscope using a Glasgow Cell-Counting Graticule (Datasights Ltd, Middlesex, UK).
Annexin-V staining was performed 2 or 3 days after FMGs transfection using annexin-V-fluorescein isothiocyanate (BD Biosciences, Le Pont-de-Claix, France). Cells were washed twice with PBS and once with 1 Â annexin-V binding buffer, and then stained with annexin-V-fluorescein isothiocyanate diluted 1:10 in 1 Â annexin-V binding buffer for 15 min at RT. After washing once with 1 Â annexin-V binding buffer, cells were incubated in sufficient 1 Â annexin-V binding buffer and observed under a fluorescence microscope. For the immunofluorescence assay, cells were fixed 3, 4 or 5 days after FMG transfection with 2% formaldehyde for 5 min in PBS, permeabilized with 2% formaldehyde supplemented with 0.2% Triton X-100 for 5 min and washed twice in PBS at RT. Cells were incubated for 1 h at RT with PBS containing 5% fetal bovine serum for blocking, and then incubated overnight at 4 1C with cleaved caspase-3 (Asp175) antibody (Cell Signaling, Boston, MA, USA) diluted 1:500 in PBS containing 5% fetal bovine serum. After three washes with PBS, cells were incubated for 1 h at RT with the secondary antibody, anti-rabbit IgG (H þ L)-fluorescein (Boehringer Mannheim Biochemicals, Meylan, France) diluted 1:500 in PBS containing 5% fetal bovine serum, and then washed three times with PBS. Cellular DNA was stained by incubating with PBS containing 1 mg ml À1 of Hoechst 33342 for 5 min at RT in all the experiments. Coverslips were mounted in Moewiol (SigmaAldrich, St Quentin Fallavier, France) and examined under a fluorescence microscope (BX 41; Olympus, Rungis, France).
MTT cell-viability assay Four or 5 days after transfection for A549 or H322, respectively, cells were washed with PBS and incubated in 180 ml of RPMI without phenol red (Invitrogen) containing 5 mg ml À1 of MTT (3-(4,5-dimethy1-2-thioazoyl) 2,5-diphenyltetrazolium bromide) (Sigma-Aldrich) at 37 1C for 3 h. Cells and the converted formazan inside were solubilized by adding 1 ml of isopropyl alcohol-0.1 M HCl and vibrated for 20 min. Viability was then determined by measuring the difference in absorbance at 570 and 655 nm (optical density 570-655).
Luciferase assay
To measure luciferase intensity, cells in 96-well plate were lysed using 20 ml per well of 1 Â passive lysis buffer (Promega) 4 (for A549 transfection) or 5 days (for H322 transfection) after the beginning of co-culture with A549-luc cells. Luminescence intensity was measured by adding 50 ml of luciferase assay substrate (Promega) to 5 ml of cell lysate, and reading for 10 s with the luminometer Lumat LB9501 (Berthold, Thoiry, France). The value of the reading was expressed as relative light units (RLUs), and the value obtained in pcDNA3.1 transfection group was set as 100% intensity.
In vivo tumor treatments
Five-week-old female Swiss nude mice (Janvier CERT, Le Genest St Isle, France) were injected subcutaneously with 2 Â 10 7 H322 cells. Eight weeks later when all mice had palpable tumors (140 mm 3 , averaged size of 25 mice), intratumoral injections of 10 mg of DNA (diluted in 100 ml of PBS) were performed every 3 days using U-100 insulin syringes (Becton Dickinson, Pont De Claix, France). Tumor volumes were measured before every DNA injection, using the following formula:
, in which a and b represent the larger and smaller diameter, respectively.
Tumor section and histochemical staining For histological analysis, tumor samples were embedded in optimal cutting temperature compound (Sakura Finetek France, Villeneuve d'Ascq, France) and stored at À80 1C. Sections measuring 10 mm in thickness were stained with hematoxylin-eosin for microscopic examination. For verification of in vivo transfection efficiency, sections were fixed by 0.5% glutaraldehyde and 1% formaldehyde and then stained by X-Gal (following the same protocol as described under section Cell fixation and staining above) and hematoxylin. (Figure 2a) . Similar results were obtained when A549 cells were used: HERV-W-FMG killed B50% of the cells, while GALV-FMG showed an even stronger killing effect (B80% loss of viability). RD-FMG was not as efficient as the other FMGs since its transfection was toxic for only 15 and 28% of the H322 and A549 cells, respectively (Figure 2a) . To check transfection efficiency, H322 and A549 cell lines were transfected by the b-galactosidase expression vector, pCMVb, under the same conditions. We observed that transfection efficiency was only 1.16 ± 0.11 and 1.1 ± 0.1% in H322 and A549 cells, respectively, as measured after X-Gal staining 2 days after transfection (Figure 2b) . Thus taken together, these results indicated that HERV-W induces the formation of syncytia as efficiently as GALV. Moreover, these syncytia efficiently induced tumor-cell death in vitro, and a strong bystander effect was involved. Indeed, up to 80% cell death resulted from only B1% of cell transfection. 
Apoptosis can be associated with FMG-induced syncytia death
The exact mechanism by which syncytia die remains unclear and previous reports have shown conflicting results. 1, 3, 7, 13 To investigate whether apoptosis plays a role in the death of syncytia in human NSCLC cells, FMG-transfected cells were stained with annexin-V and also with an anti-active caspase-3 antibody (Figure 4) . Positive staining was obtained with both the methods when GALV-FMG was used in A549 cells (Figures 4a  and b) . Active caspase-3 was detected as early as 3 days after GALV-FMG transfection. One day later (day 4), the numerous nuclei present in each syncytia appeared fragmented (Figure 4d) . In order to confirm the role of apoptosis in syncytial death, we incubated the FMGtransfected A549 cells with the broad-spectrum caspase inhibitor Z-VAD (Figure 4e ), or co-transfected the 
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GALV-FMG with antiapoptotic genes Bcl-XL or Bcl-2 ( Figure 4f ). Nevertheless, none of these treatments were able to prevent the GALV-mediated toxicity in A549 cells. Finally, annexin-V or active caspase 3 staining was not observed in H322 cells transfected by any FMG, including GALV ( Figure 4c ). Altogether, these results suggest that even though apoptosis may sometime be involved in FMG-mediated cell death, it is certainly not the unique mechanism responsible of the death of syncytia.
FMG inhibits tumor growth in vivo
To test the antitumor activity of FMG in vivo, human H322 subcutaneous tumors were grafted in nude mice and transfected by direct intratumoral injection of naked plasmids expressing the FMGs. H322 tumor is especially sensitive to transfection after direct intratumoral injection of naked DNA, as described previously, 26-28 but A549 tumor is not. We, thus, used only the H322 tumor model in vivo.
Plasmids were injected every 2 or 3 days for more than 1 month ( Figure 5 ). No significant growth inhibition was observed on tumors treated by RD-FMG or with the pCMVb plasmid, which served as negative control. In contrast, transfection of GALV-FMG rapidly and significantly slowed down tumor progression. HERV-W-FMG-treated tumors seemed not affected during the first 25 days, but this was mainly observed for two animals with large tumors. After removing the necrotic liquid at day 26, the toxic effect of HERV-W was visible on the curve. The final volume of these tumors was similar to those treated by GALV-FMG (Figure 5a ).
The weight of the tumors was measured at the end of the experiment (Figure 5b ). As expected, HERV-W-or GALV-treated tumors were significantly smaller, with mass only 32 and 42% of that the control group, respectively (Po0.01).
We then counted the number of syncytia formed in these tumors (Figures 6a and b) . The presence of multinucleated cells was verified in each sample and no statistical difference was noticed after counting the number of syncytia in the samples obtained from the three FMG-treated groups (Figure 6b) . Staining of the control sample with X-Gal (Figure 6c ) allowed us to confirm the very low transfection efficiency due to direct intratumoral injection of the naked plasmid, with the presence of individualized transfected cells only.
Altogether, these results confirmed those obtained in vitro, showing that HERV-W FMG, like GALV, efficiently induced tumor-cell death via a strong bystander effect. In these assays, RD-FMG did not show activity sufficient to be used in gene therapy protocols relying only on syncytia formation.
Discussion
Since the year 2000, FMGs have been applied to tumor therapy because of their cytotoxic effect on cancer cells, their ability to induce antitumor immunization in vivo and their adjuvant utility with other therapy strategies such as oncolytic adenovirus, HSV, vesicular stomatitis virus or chemotherapy. [1] [2] [3] [4] [7] [8] [9] [10] [11] [12] [13] [14] [15] In this study, we demonstrate that HERV-W FMGs' cytotoxicity resulting from the formation of gigantic cells is sufficient to induce tumor regression, with a very strong bystander effect, after non-viral, intratumoral gene delivery as previously described for GALV.
FMG-mediated antitumor activity relies strongly on the existence of a powerful bystander effect. Indeed, in agreement with other reports, we observed that FMGexpressing cells can fuse with 50 to 100 neighboring cells 1 and form multinucleated syncytia, which efficiently died (Figures 1 and 2) . The bystander cytotoxic effect is particularly strong since up to B80% of cell death was obtained in vitro, while only B1% of the cells were transfected (Figure 2 ). This bystander effect can also induce the death of a co-cultured cell line, which was not transfected by any FMG (Figure 3 ). The bystander effect is an important issue in cancer gene therapy since efficient delivery of DNA remains a major problem in vivo. This bystander effect can be also obtained by other means such as VP22-mediated protein diffusion or suicide genes like thymidine kinase. VP22 is an HSV tegument protein, with unusual intercellular trafficking properties allowing it to spread from one producing (transfected) cell to numerous surrounding cells. 29 Fusion proteins between VP22 and a therapeutic polypeptide were thus successfully used for in vivo tumor therapy although conflicting results have also been reported. 27, 28, [30] [31] [32] [33] [34] [35] Positive gene therapy results using suicide genes like the herpes simplex type-1 thymidine 
H322 cells
Relative RLU(%) Relative RLU(%) Figure 3 The bystander effect of FMG-induced cell death. A549 and H322 cells were transfected by FMGs and then co-cultured with the A549-luc stable clone. Luciferase intensity was measured 4 (A549) or 5 days (H322) after the beginning of the co-culture. The pcDNA3.1 transfection group was used as negative control (100% RLUs). The results were averaged from two independent experiments (n ¼ 10). Error bars indicate the s.d. FMG, fusogenic membrane glycoprotein.
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kinase (HSV-TK) associated with the injection of a prodrug (ganciclovir) were also largely documented. However, despite numerous and encouraging preclinical results, this strategy has not been very successful so far in clinical trials, in part because of the poor efficiency of the gene transfection methods, and also because the bystander effect in human beings was not as strong as in rodent cells. 36, 37 As compared with VP22 or HSV-TK, FMG presents advantages because once expressed on the cell surface, it simply recruits a large number of neighbor cells into one single, growing syncytium committed to die.
However, a possible limitation could come from poor fusogenic activity if the adequate cell-surface receptor is not present on the tumor cells. Nonetheless, commonly used FMGs such as GALV-FMG or MV-F and MV-H seem to be able to fuse all the tested human cancer cell lines so far, and a previous report has demonstrated a 10 times more stronger bystander effect using GALV-FMG than HSV-TK. 3 How and why these syncytia die is still an issue and our study is confirming the conflicting results presented in several reports. It has been shown that most syncytia 
induced by MV-F and MV-H or GALV-FMG in cultured glioma cell lines showed the characteristics of TUNELpositive, fragmented genomic DNA 6 days after FMG transfection. 7 Nevertheless, the same TUNEL assay performed using several other cell lines after GALV-FMG transfection did not confirm the presence of apoptotic DNA at any stage of development of the syncytia. 3 Similar negative results were obtained using other methods of apoptosis detection (activation of procaspase-3 and PARP) in human fibrosarcoma or osteosarcoma cells transfected by GALV or MV-F and MV-H. 13 In our study, apoptosis seems to be involved in the GALV-FMG-mediated death of the human A549 NSCLC cells, but not when the HERV-W-or RD-FMGs were used (Figures 4a and b) . Nonetheless, this result was not reproduced in another human NSCLC cell line, H322, in which none of the tested FMGs, including GALV, induced caspase-3 activation (Figure 4c ). In addition, neither the presence of the broad-spectrum caspase inhibitor Z-VAD, nor co-transfection of Bcl-XL or Bcl-2, which are very potent inhibitors of the mitochondriondependant apoptosis, did prevent GALV-FMG-induced cell death (Figures 4e and f) . Thus, our results suggest that induction of apoptosis in these syncytia is FMG-and cell line-dependent and is certainly not the unique mechanism involved in syncytial death. It has been shown that Respiratory Syncytial Virus can block early apoptosis of infected cells through a p53-dependent pathway and phosphatidyl inositol-3kinase/AKT activation, 38 while its F fusogenic protein is capable of inducing p53-dependent apoptosis. 39 The presence or absence of the p53 tumorsuppressor protein may thus contribute to explaining the differences we observed between the two NSCLC cell lines A549 (P53 WT) and H322 (p53À/À) in response to GALV-induced syncytia death. Finally it must be noticed that unfused tumor cells surrounding FMG-positive syncytia were very often positively labeled by the antiactive caspase-3 antibody, as can be observed in Figure 4b . One hypothesis to explain this observation would be that the dying syncytia release toxic factors. Such a mechanism has been described for eosinophils, neutrophils and mast cells during bacterial infection. [40] [41] [42] Eosinophils are able to kill extracellular bacteria by rapidly releasing 'toxic mitochondrial DNA' in a catapultlike manner, 40 a process independent of eosinophil death. On the other hand, neutrophils can form neutrophil extracellular traps-structures composed of chromatin and granule proteins, which bind and kill extracellular microorganisms. Upon bacterial stimulation, the nuclei of neutrophils lose their shape and the nuclear envelope and the granule membranes disintegrate, allowing mixing of the components of the neutrophil extracellular trap. Finally, the neutrophil extracellular traps are released as the cell membrane breaks. This cell death process is distinct from apoptosis or necrosis and depends on generation of reactive oxygen species by NADPH oxidase. 41 It could, thus, be possible that dying syncyctia release toxic factors like neutrophil extracellular traps in their surroundings to mediate the death of unfused cells, thus augmenting the bystander effect.
Previous studies established successful treatments of human glioma or fibrosarcoma xenografts on mouse model after intratumoral delivery of GALV-FMG or MV-F and MV-H genes. [3] [4] [5] 7 However, these results were mostly based on repeated treatments with high doses of the vectors injected at very early stage of tumor development (3 days after subcutaneous implantation, 0.1-0.4 cm in diameter). In our study, the antitumor effect of FMGs was measured on human H322 lung tumors after repeated intratumoral injections of naked DNA in relatively large and solid tumors (X0.6 cm in diameter). It is important to notice that H322 is the only cancer cell line we know of that can be transfected by direct intratumoral injection of naked DNA. However, the transfection efficiency is still low (o1% of the tumor cells), but we previously demonstrated that it is sufficient to successfully deliver p53-, bax-or p27-encoding plasmids. [26] [27] [28] In this study, we show that despite this very low transfection efficiency, a significant reduction of tumor growth can be observed after direct intratumoral injection of HERV-W-or GALV-, but not RD-FMG-encoding plasmids. This strong antitumor response suggests that FMG genes and especially HERV-W and GALV are very potent and promising tools for the treatment of human lung tumors, especially in immunecompetent animals where we know that this direct cell-killing activity of FMG will also be supported by release of highly immunogenic exosome-like vesicles. 13 These vesicles, also called syncytiosomes, could also prime an immune-antitumor response. FMGs are thus promising therapeutic genes for treatment of tumors.
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